Skip to content
The Kids Research Institute Australia logo

Jane Oliver

Senior Research Officer

Jane Oliver

BMLSc, PGDipMLSc (Credit), MHealSc (Distinction), PhD

Senior Research Officer

jane.oliver@thekids.org.au

https://www.linkedin.com/in/jane-oliver-0b01ab120/

Dr Jane Oliver is a scientist at The Kids Research Institute Australia. She is an Adjunct Research Fellow at the University of Western Australia and has an honorary role at the University of Melbourne. Her research addresses multiple public health issues, including infectious diseases and the impact of socio-environmental factors on health outcomes.

Dr Oliver’s major research interest is the control and prevention of rheumatic heart disease (RHD). As a Senior Research Officer, she holds an integral role within the End Rheumatic Heart Disease program, which aims to eradicate this potentially life-threatening disease. Dr Oliver is currently running several clinical trials evaluating a novel treatment option for RHD prophylaxis in partnership with Aboriginal communities. She is privileged to work closely with Aboriginal collaborators and mentors, including acclaimed Elders and community members with firsthand experience of RHD.  

Dr Oliver’s focus on addressing RHD began with her University of Otago master’s degree (2013), when she was funded by the New Zealand Ministry of Health to evaluate the rheumatic fever surveillance sector. Recommendations from her thesis continue to guide national reporting today. Her doctorate (University of Otago, 2018) revealed novel risk factors for RHD and provide guidance for RHD prevention efforts globally, particularly regarding antibiotic stewardship. 

As a Postdoctoral Fellow based jointly at the University of Melbourne and Murdoch Children’s Research Institute, Dr Oliver applied her epidemiological and qualitative skillsets to reveal ongoing morbidity from Strep A diseases. Australian health departments responded by making invasive Strep A disease nationally notifiable, and making ARF and RHD notifiable in Victoria. Other infectious disease research which Dr Oliver oversaw provided insights into Buruli ulcer transmission pathways, informing the Victorian epidemic response. Her COVID-19 diagnostic studies enhanced testing early in the pandemic, and later qualitative research guided national vaccine communications. Findings from her community co-designed evaluation of a COVID-19 health promotion program helped to establish the Community Connectors initiative, which works to enhance social housing residents’ access to services. 

Dr Oliver has been based at The Kids Research Institute since early 2024, continuing her focus on reducing suffering from RHD. Her research teams have received multiple awards, including the 2014 New Zealand Prime Ministers’ Science Prize, the 2023 Liley Medal and a Finalist placing in the 2024 Australian Museum Eureka Prizes.

Published research

Increased burden of invasive group A streptococcal disease among Australian children, 2023–2024: a prospective cohort study

Global rates of invasive Group A Streptococcus (iGAS) disease surged from September 2022, exceeding pre-COVID-19 pandemic levels, showing atypical seasonality and disproportionately affecting children. We previously described the epidemiology of iGAS among Australian children from mid-2018 to end 2022 using data from the Paediatric Active Enhanced Diseases network and here provide updated clinical epidemiology for 2023 and 2024 to help inform public health strategies.

Published research Infectious Diseases Invasive Streptococcus A Disease COVID-19 Penicillin Team
Learn more about Increased burden of invasive group A streptococcal disease among Australian children, 2023–2024: a prospective cohort study

April 2026

Subcutaneous Infusion of Benzathine Penicillin G Is Acceptable and Preferred Over Intramuscular Injections for Syphilis in Western Australian Sexual Health Clinic Attendees

Controlling the syphilis epidemic in Australia is a public health priority. Regular intramuscular (IM) injections of benzathine penicillin G (BPG) are the current standard of care for late latent syphilis in Australia; however, repeated IM BPG injections are painful, and treatment completion rates are low. Early-phase clinical trials have demonstrated the tolerability and safety of high-dose subcutaneous infusions of BPG (SCIP), where the total treatment dose can be delivered at a single visit. Here we describe the experiences and preferences of attendees of Western Australian sexual health clinics in the Perth metropolitan region who have syphilis and were treated with SCIP.

Published research Immunisation Infectious Diseases Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases Healthy Skin and ARF Prevention Penicillin Team
Learn more about Subcutaneous Infusion of Benzathine Penicillin G Is Acceptable and Preferred Over Intramuscular Injections for Syphilis in Western Australian Sexual Health Clinic Attendees

September 2025

Estimating the true number of people with acute rheumatic fever and rheumatic heart disease from two data sources using capture-recapture methodology

In Australia, accurate case ascertainment of acute rheumatic fever (ARF) and rheumatic heart disease (RHD) diagnoses for disease surveillance and control purposes requires the use of multiple data sources, including RHD registers and hospitalisation records. Despite drawing on multiple data sources, the true burden of ARF/RHD is likely to be underestimated.

Published research Rheumatic Heart Disease Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases Penicillin Team
Learn more about Estimating the true number of people with acute rheumatic fever and rheumatic heart disease from two data sources using capture-recapture methodology

March 2025